What is the main business of Biogen Poland?

The main business activity of Biogen Poland focuses on advertising agencies.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on October 15, 2010.

Where is the headquarters located?

The headquarters is located at: ul. Prosta 18, 00-850 Warszawa.

Who is on the management board?

The management board includes Piotr Dębski (Member of the Management Board).

What is the share capital?

The share capital of the company is PLN 1,500,000 (approx. $405,186).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

In 2025, the company generated total revenue of $42,610,046, representing an increase of 10.5% compared to 2024.

Is the company profitable?

Yes, in 2025 the company was profitable, achieving a net profit of $1,634,397, meaning the company increased its profit by 0.5%.

Which cost dominates operating expenses?

The largest operating cost category falls under employee remuneration. This category amounted to $24,121,783 in 2025, representing 60% of all operating expenses.

Biogen Polandsp. z o.o.

Advertising agencies

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2010-10-15

Share capital

1,500,000.00 PLN

Activity description

Biogen Poland is a biotechnology company developing therapies for complex and debilitating diseases. It advances potential treatments in neurology, neuropsychiatry, immunology and rare diseases.

Registered address

ul. Prosta 18, 00-850 Warszawa, Poland

Website

biogen-poland.pl

Phone

Social media

Electronic delivery address

AE:PL-31180-30430-RVSES-16

Financials

Revenue history (in m)

Filing timeliness

6 of 6 financial statements were filed late (the longest delay 375 days for 2023). All were audited by a statutory auditor.

202516/07/2026
202401/12/2025
202325/07/2025
202216/05/2024
202109/12/2022
202027/01/2022

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 42.61mMedianUSD 115.83kAverageUSD 1.11m

Net profit

This companyUSD 1.63mMedianUSD 4.00kAverageUSD 74.68k

Operating costs

This companyUSD 40.48mMedianUSD 100.69kAverageUSD 1.01m

Assets

This companyUSD 21.06mMedianUSD 57.32kAverageUSD 667.63k

Industry

Offer

Biologic medicines
Neurological therapies
Neuropsychiatric therapies
Immunological therapies
Rare disease therapies

Website technology

Analytics and marketing

Google Tag Manager

Authorized Representatives

Anna Biskup – Management Board Member

Katarzyna Borawska – Management Board Member

Sérgio Da Silva Teixeira – Management Board Member

Piotr Dębski – Management Board Member

Francesco Verolino – Management Board Member

Manner of representation

Each member of the company's management board has the right to represent the company independently.

Ownership

Owner	Shares	Share value	Stake
Biogen Ma Inc.	30,000	$405,186.39	100%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2010-08-27.

Erste Bank Polska
15 1090 2851 0000 0001 3726 2116

Debt

No entries in the National Debtors Register (KRZ).

Real estate

Type	Amount
Buildings and premises	PLN 3.1MPLN 3,100,490

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name	Revenue	Website
Janssen-Cilag Polskasp. z o.o.	$323,933,929.12	janssen.pl
Pfizer Polskasp. z o.o.	$110,632,345.55	pfizer.pl
MSD Polskasp. z o.o.	$99,368,700.21	msd.pl

Change history

Date	Event
2023-09-18	Address change (Ul. Salsy 2, 02-823, Warszawa → Ul. Prosta 18, 00-850, Warszawa)
2016-09-07	Address change (Ul. Osmańska 12a, 02-823, Warszawa → Ul. Salsy 2, 02-823, Warszawa)
2015-12-14	Address change (Poleczki 35, 02-822, Warszawa → Ul. Osmańska 12a, 02-823, Warszawa)
2015-03-19	Name change (Biogen Idec Poland → Biogen Poland)
2013-02-15	PKD change (Added: 73.11.Z, 85.59.B)

FAQ

Last updated: 2026-10-07